• The Blood Based Biomarkers market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 18.50 billion by 2034. Growth is anchored in the rising burden of cancer, cardiovascular, and neurological disease, the shift toward non-invasive testing, and a wave of regulatory clearances led by the first blood tests for Alzheimer's disease.

• The global Blood Based Biomarkers market is growing at a CAGR of 9.0% during the forecast period from 2026 to 2034.

• By type, the genetic biomarkers segment dominated the Blood Based Biomarkers market with a 41% share in 2025.

• By application, the oncology segment dominated the Blood Based Biomarkers market with a 39% share in 2025.

• By technology, the immunoassays segment dominated the Blood Based Biomarkers market with a 36% share in 2025.

• By end user, the hospital and diagnostic laboratories segment dominated the Blood Based Biomarkers market with a 48% share in 2025.

• North America dominated the global Blood Based Biomarkers market revenue with a 44% share in 2025, representing the highest regional market share globally.

Blood based biomarkers are measurable biological indicators in the blood, including proteins, nucleic acids, cells, and metabolites, that provide information about a person's health, disease presence and progression, and response to treatment. Detected through minimally invasive blood draws, these biomarkers include genetic markers such as cell-free DNA, circulating tumor DNA, and microRNA, protein markers such as troponin, phosphorylated tau, and prostate-specific antigen, circulating tumor and other cells, and metabolites such as glucose and glycated hemoglobin. They are increasingly central to the early detection, diagnosis, monitoring, and management of cancer, cardiovascular disease, neurological disorders, metabolic conditions, and infectious diseases, and they support companion diagnostics, recurrence monitoring, and clinical-trial enrichment. The market spans biomarker types, detection technologies including immunoassays, polymerase chain reaction, next-generation sequencing, and mass spectrometry, and applications across hospitals, diagnostic and reference laboratories, and research settings. Propelled by the rising burden of chronic and age-related disease, the maturation of liquid biopsy, a transformative wave of blood tests for Alzheimer's disease, and the broad shift from invasive tissue biopsy toward fast, safe, repeatable blood testing, blood based biomarkers have become foundational infrastructure for precision and preventive medicine.

Blood Based Biomarkers Market Key Growth Drivers

• The rising global cancer burden is driving demand for blood-based oncology biomarkers, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.

• The growing prevalence of neurological disorders such as Alzheimer's and Parkinson's disease, alongside aging populations, is driving demand for non-invasive blood-based diagnostics.

• A transformative wave of regulatory clearances for blood tests, including the first FDA-cleared blood test to aid Alzheimer's diagnosis in 2025, is accelerating clinical adoption.

• The maturation of liquid biopsy is enabling sensitive detection of circulating tumor DNA for cancer detection, treatment selection, and recurrence monitoring.

• The broad shift from invasive tissue biopsy toward faster, safer, and repeatable blood testing is expanding adoption across screening, diagnosis, and monitoring.

• Advances in artificial intelligence, proteomics, and multi-biomarker panels are improving accuracy and enabling predictive, risk-based precision diagnostics.

• The convergence of disease burden, non-invasive testing, regulatory progress, and technological advances is expected to sustain strong growth in the market through 2034.

Key Companies in Blood Based Biomarkers Market

The competitive landscape is led by the following active developers and providers:

• F. Hoffmann-La Roche Ltd

• Abbott Laboratories

• Siemens Healthineers AG

• Thermo Fisher Scientific Inc.

• Quest Diagnostics Incorporated

• Laboratory Corporation of America Holdings

• Bio-Rad Laboratories, Inc.

• Quanterix Corporation

• Fujirebio Holdings, Inc.

• Guardant Health, Inc.

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies, where relevant to the market assessment.

Blood Based Biomarkers Market Size

The following snapshot summarizes the principal report metrics for the Blood Based Biomarkers market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

 

Factors Contributing to the Growth of the Blood Based Biomarkers Market

Market Drivers

Rising Global Cancer Burden and Liquid Biopsy Adoption

The most powerful driver of the blood based biomarkers market is the rising global cancer burden, coupled with the rapid adoption of liquid biopsy. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, and oncology is the largest application for blood-based biomarkers. Liquid biopsy enables sensitive detection of circulating tumor DNA, often at low mutant allele frequencies, supporting early detection, treatment selection, and recurrence monitoring without invasive tissue sampling. Clinical studies have shown that a substantial share of advanced cancer patients carry actionable circulating tumor DNA mutations detectable only by blood-based testing, including resistance mutations that guide therapy. Genetic biomarkers such as circulating tumor DNA and cell-free DNA anchor the largest segment of the market. As cancer incidence climbs and liquid biopsy matures, demand for blood-based oncology biomarkers expands, anchoring market growth through the forecast period. 

Growing Burden of Neurological Disease and the Alzheimer's Blood Test Revolution

The growing burden of neurological disease, led by Alzheimer's and Parkinson's, is the fastest-growing driver of the market. As populations age, the prevalence of dementia and neurodegenerative disorders rises, and blood-based biomarkers offer a simpler, faster, and less invasive alternative to costly amyloid positron-emission-tomography imaging and cerebrospinal-fluid testing. A transformative wave of blood tests for Alzheimer's has emerged, anchored by phosphorylated tau biomarkers such as pTau217 and pTau181, which consistently outperform earlier generations for detecting amyloid and tau pathology. The first FDA-cleared blood test to aid Alzheimer's diagnosis reached the United States market in 2025, professional-society guidelines now endorse high-performing blood tests for triage and, in appropriate patients, substitution for imaging or spinal-fluid testing, and the World Health Organization has issued preferred product characteristics for these diagnostics. This convergence of disease burden, clinical validation, and guideline support is rapidly expanding neurological blood-based biomarker demand across the forecast period. 

Accelerating Regulatory Clearances and Guideline Support

Accelerating regulatory clearances and professional-guideline support are building clinical trust and adoption. In 2025, the FDA granted marketing clearance for the first blood test to aid the diagnosis of Alzheimer's disease, a plasma phosphorylated tau and amyloid ratio assay, quickly followed by a nationwide laboratory launch, and additional plasma tau tests for primary-care assessment subsequently secured clearance. The FDA had earlier granted Breakthrough Device Designation to plasma pTau217 testing, and it has cleared point-of-care blood biomarker tests for conditions such as traumatic brain injury. In parallel, the Alzheimer's Association issued its first clinical practice guideline endorsing high-performing blood biomarker tests, and the World Health Organization published preferred product characteristics for Alzheimer's blood diagnostics. These regulatory and guideline milestones reduce adoption friction, support reimbursement, and move blood-based biomarkers from research into routine clinical practice, directly driving market growth across the forecast period. 

Shift toward Non-Invasive and Preventive Testing

The broad shift toward non-invasive, preventive testing is a central driver of adoption. Compared with tissue biopsies and many imaging procedures, blood tests are faster, safer, more comfortable, and easily repeatable, making them well suited to routine screening, early diagnosis, and long-term monitoring. Their minimally invasive nature allows frequent testing and straightforward integration into clinical workflows and primary care, broadening the populations that can be screened and monitored. Blood-based biomarkers can detect disease before symptoms appear, supporting earlier intervention and improved outcomes across cancer, cardiovascular disease, and neurological conditions, and they enable real-time monitoring of disease progression and treatment response. As health systems and patients increasingly prioritize preventive, value-based, and patient-centric care, the convenience and repeatability of blood-based testing drive rising demand, reinforcing market growth across the forecast period. 

Maturation of Molecular Diagnostics and Ultra-Sensitive Detection

The maturation of molecular diagnostics and ultra-sensitive detection technologies is expanding the capability and reach of blood-based biomarkers. Advances in next-generation sequencing, digital polymerase chain reaction, ultra-sensitive immunoassays, mass spectrometry, and proteomics have raised the sensitivity and specificity needed to detect rare circulating tumor DNA, low-abundance neurological proteins, and other faint signals in blood. Ultra-sensitive single-molecule immunoassay platforms enable detection of neurological biomarkers for Alzheimer's and Parkinson's at earlier stages, while sequencing and digital polymerase chain reaction support comprehensive genomic profiling and minimal residual disease monitoring in oncology. Falling sequencing costs, improved multiplexing, and the integration of bioinformatics enhance accuracy and clinical utility. As detection technologies advance and costs decline, blood-based biomarkers become more accurate, affordable, and broadly applicable, driving adoption across clinical and research settings throughout the forecast period. 

Advances in Artificial Intelligence and Multi-Biomarker Panels

Advances in artificial intelligence and multi-biomarker panels are transforming biomarker discovery and diagnostic accuracy. Machine-learning and deep-learning models analyze large, complex datasets to identify disease patterns, interpret multiplexed biomarker signatures, and predict health risks, shifting the field from single-biomarker diagnostics toward predictive, risk-based, and precision approaches. Multi-analyte panels combining proteins, nucleic acids, and metabolites improve sensitivity and specificity across cancer, neurological, and cardiovascular applications, and proteomic platforms measuring hundreds of proteins are achieving high accuracy in early disease detection. Artificial intelligence also accelerates biomarker discovery, supports clinical-trial enrichment, and enhances the interpretation of genomic and proteomic data. As these computational and multiplexing capabilities mature, they raise diagnostic performance, broaden the range of detectable conditions, and strengthen the clinical and economic case for blood-based biomarkers, reinforcing the market's long-term growth trajectory across the forecast period. 

Expanding Use in Drug Development and Companion Diagnostics

The expanding use of blood-based biomarkers in drug development and companion diagnostics is a durable source of demand. Pharmaceutical and biotechnology companies increasingly rely on blood-based biomarkers to enrich and stratify clinical trials, monitor treatment response, and demonstrate target engagement, improving trial efficiency and success rates. The rise of disease-modifying therapies, particularly in Alzheimer's disease and oncology, creates strong demand for companion and complementary diagnostics that identify eligible patients and monitor therapy, and blood-based tests that detect amyloid pathology or actionable mutations are central to this model. Partnerships between diagnostics developers and pharmaceutical companies are accelerating the co-development of tests and therapies. As precision medicine and targeted therapies proliferate, the integration of blood-based biomarkers into drug development and companion diagnostics deepens, creating sustained demand across both clinical and life-sciences markets and reinforcing market growth through the forecast period. 

Market Restraints

Despite strong momentum, the blood based biomarkers market faces material constraints. Analytical and clinical validation requirements are demanding, as blood-based tests must demonstrate high sensitivity and specificity across diverse populations and disease stages, and many biomarkers show lower sensitivity for early-stage disease, raising the risk of false negatives that provide false reassurance and false positives that trigger costly, anxiety-inducing confirmatory workups. Reimbursement remains uneven and immature across geographies and applications, and many advanced tests are offered as self-pay or laboratory-developed tests without broad payer or public coverage, constraining access and return on investment. Regulatory pathways are still evolving, particularly for novel and multi-analyte tests, lengthening development timelines and adding uncertainty, and the absence of approval for many tests limits guideline inclusion. Standardization and harmonization gaps across platforms, assays, and reference ranges complicate comparability and clinical interpretation, and the need for confirmatory imaging or tissue testing in some settings limits standalone use. High costs of advanced platforms and the need for specialized infrastructure and expertise constrain adoption, particularly in lower-resource settings, and data-privacy, governance, and equity considerations add complexity. Clinician and patient awareness remains uneven, and uncertainty about real-world impact on outcomes pending long-term evidence tempers uptake. Together, these validation, reimbursement, regulatory, standardization, and infrastructure barriers moderate the pace of growth, even as the underlying drivers of disease burden and non-invasive testing remain firmly intact.

 

Blood Based Biomarkers Market Segment Analysis

The Blood Based Biomarkers Market by Type (Genetic Biomarkers, Protein Biomarkers, Cellular Biomarkers, Metabolite Biomarkers), Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic and Other Diseases), Technology (Immunoassays, Polymerase Chain Reaction, Next-Generation Sequencing, Mass Spectrometry, Others), End User (Hospital and Diagnostic Laboratories, Reference Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Type

Dominant Subsegment: Genetic Biomarkers. The genetic biomarkers category is expected to dominate the market.

Dominant:  Genetic Biomarkers ~ 41%

The genetic biomarkers segment accounted for 41% of the Blood Based Biomarkers market in 2025. Genetic biomarkers are the leading type because circulating tumor DNA, cell-free DNA, microRNA, and other nucleic-acid markers anchor the high-value, fast-growing field of liquid biopsy in oncology, the largest application for blood-based biomarkers. These markers detect the presence of tumors, guide treatment selection, identify resistance mutations, and monitor minimal residual disease and recurrence, capturing substantial clinical and commercial value. The rising incidence of cancer, advances in sequencing and digital polymerase chain reaction, and growing demand for personalized medicine reinforce the segment's dominance, as genetic profiles increasingly direct targeted therapy. Protein biomarkers form a very large and established category, spanning cardiac troponin, prostate-specific antigen, and the phosphorylated tau markers driving the Alzheimer's blood-test wave, while cellular biomarkers, including circulating tumor cells, are the fastest-growing type as genomics and proteomics research and precision medicine expand, and metabolite biomarkers support metabolic disease. Nonetheless, the value, growth, and oncology centrality of genetic biomarkers secure their leadership across the forecast period.

By Application

Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.

Dominant:  Oncology ~ 39%

The oncology segment accounted for 39% of the Blood Based Biomarkers market in 2025. Oncology is the leading application because blood-based biomarkers are central to cancer detection, treatment selection, recurrence monitoring, and companion diagnostics, and because the rising global cancer burden continuously expands testing volumes. Liquid biopsy and circulating tumor DNA testing enable non-invasive detection of actionable mutations, minimal residual disease monitoring, and recurrence surveillance, and established tests detect circulating tumor DNA to guide therapy without tissue biopsy. The breadth of cancer types, the large and growing patient population, and strong research and development investment anchor the segment's dominance. Cardiovascular disease is a large application, anchored by high-volume cardiac biomarkers such as troponin for heart-attack detection and risk stratification, while neurological diseases are the fastest-growing application, propelled by the Alzheimer's blood-test wave and demand for non-invasive neurodegenerative diagnostics, and metabolic and other diseases contribute through markers such as glucose and glycated hemoglobin. Nonetheless, the scale, value, and research momentum of oncology secure its leadership across the forecast period.

By Technology

Dominant Subsegment: Immunoassays. The immunoassays category is expected to dominate the market.

Dominant:  Immunoassays ~ 36%

The immunoassays segment accounted for 36% of the Blood Based Biomarkers market in 2025. Immunoassays are the leading technology because they underpin the largest volume of routine blood-based protein-biomarker testing across cardiology, oncology, and neurology, run on widely installed automated platforms in hospitals and laboratories worldwide. High-throughput immunoassay systems measure markers such as cardiac troponin, prostate-specific antigen, and the phosphorylated tau biomarkers driving the Alzheimer's blood-test wave, including ultra-sensitive single-molecule platforms that detect low-abundance neurological proteins. The vast installed base, established reimbursement for many immunoassay tests, and the recent clearances of plasma tau immunoassays reinforce the segment's dominance. Next-generation sequencing and polymerase chain reaction are critical and fast-growing technologies underpinning genetic biomarkers and liquid biopsy, and together they capture a large share of oncology molecular testing, while mass spectrometry supports proteomic and metabolomic analysis. Nonetheless, the breadth, volume, and installed base of immunoassay testing secure the segment's leadership across the forecast period.

By End User

Dominant Subsegment: Hospital and Diagnostic Laboratories. The hospital and diagnostic laboratories category is expected to dominate the market.

Dominant:  Hospital and Diagnostic Laboratories ~ 48%

The hospital and diagnostic laboratories segment accounted for 48% of the Blood Based Biomarkers market in 2025. Hospital and diagnostic laboratories are the largest end user because they perform the overwhelming majority of blood-based biomarker tests, from routine cardiac and oncology markers to the new generation of neurological assays, and have the platforms, throughput, and clinical integration to deliver them at scale. These laboratories order, run, and interpret tests, integrate results into patient care, and coordinate follow-up, making them central to clinical adoption, and the recent nationwide laboratory launches of Alzheimer's blood tests illustrate their pivotal role. Reference laboratories are a large and fast-growing end user, performing complex, specialized, and high-sensitivity assays such as liquid biopsy and ultra-sensitive neurological testing, while academic and research institutes drive biomarker discovery and validation, and pharmaceutical and biotechnology companies use blood-based biomarkers for clinical trials and companion diagnostics. Nonetheless, the volume, infrastructure, and clinical centrality of hospital and diagnostic laboratories secure their leadership across the forecast period.

 

Blood Based Biomarkers Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global Blood Based Biomarkers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high healthcare spending, and strong adoption of advanced diagnostics, a high burden of cancer and neurological disease, and the concentration of leading diagnostics companies, particularly in the United States. North America leads in regulatory clearances and clinical adoption, exemplified by the 2025 FDA clearance of the first blood test to aid Alzheimer's diagnosis and its rapid nationwide laboratory launch, the clearance of plasma tau tests for primary care, and earlier clearances of point-of-care brain-injury biomarker tests. The region hosts a deep pool of diagnostics leaders and liquid-biopsy innovators, robust oncology and neurology pipelines, significant research funding, and growing payer engagement, supported by professional-society guidelines endorsing blood-based testing. Strong infrastructure, regulatory leadership, and innovation anchor the region's continued leadership across the forecast period.

Dominant:  North America ~ 44% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Blood Based Biomarkers market. The region's elevated CAGR is driven by a large and aging population, a rising burden of cancer, cardiovascular, and neurological disease, expanding healthcare access and investment, and growing adoption of advanced diagnostics across China, Japan, India, South Korea, and Australia. Increasing awareness of liquid biopsy and non-invasive testing, expanding laboratory infrastructure, government initiatives to improve early diagnosis, and strong regional diagnostics and research activity are accelerating adoption. Japan in particular is advancing neurodegenerative-disease diagnostics, and regional players are scaling cost-effective testing. Rising chronic-disease prevalence, growing healthcare expenditure, and expanding access position Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Blood Based Biomarkers market revenue in 2025. The United States dominates on the strength of advanced infrastructure, high healthcare spending, regulatory leadership including the first FDA-cleared Alzheimer's blood test, a dense base of diagnostics and liquid-biopsy companies, and strong research funding, while Canada contributes through oncology liquid-biopsy and neurology adoption.

Europe

Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong public health systems, rising awareness of liquid biopsy and blood-based testing, active neurodegenerative-disease research, and a robust base of diagnostics companies, while the in vitro diagnostic regulation shapes the evidence requirements and adoption of new tests across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large aging population, rising cancer, cardiovascular, and neurological disease burden, expanding healthcare access and investment, and growing adoption of advanced diagnostics across China, Japan, India, South Korea, and Australia. Regional diagnostics players scale cost-effective testing, while government early-diagnosis initiatives and neurodegenerative-disease research broaden access.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging contributor. A rising burden of cancer and chronic disease, expanding healthcare access, and growing interest in non-invasive diagnostics are creating early demand, while partnerships, laboratory capacity building, and improving reimbursement gradually extend access to blood-based biomarker testing across these markets over the forecast period.

 

Blood Based Biomarkers Market Competitive Landscape

The Blood Based Biomarkers market is classified as Moderately Concentrated. A group of large diagnostics leaders, including Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific, holds substantial share through broad immunoassay and molecular platforms, extensive clinical evidence, and global distribution, while a dynamic field of laboratory networks and specialized innovators, including Quest Diagnostics, Labcorp, Quanterix, Fujirebio, Guardant Health, and other liquid-biopsy and neurodegenerative-biomarker players, intensifies competition through novel biomarkers and advanced detection technologies.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with large diagnostics leaders alongside a dynamic field of laboratory networks and specialized liquid-biopsy and neuro innovators.

• Leading players: Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific anchor the top tier through broad platforms and clinical evidence.

• Geographic reach: Leaders operate global commercial and laboratory networks, with strong positions across North America, Europe, and Asia-Pacific.

• Product portfolio strength: Top players hold integrated immunoassay, molecular, and sequencing portfolios spanning oncology, cardiology, and neurology.

• Pipeline and evidence strength: Regulatory clearances and large clinical datasets, such as the first FDA-cleared Alzheimer's blood tests, are decisive competitive assets.

• Strategic partnerships: Collaborations between diagnostics and pharmaceutical companies, such as Biogen with Beckman Coulter and Fujirebio, accelerate test development.

• M&A activity: Active consolidation as players acquire biomarker technologies and liquid-biopsy and neurodegenerative capabilities to broaden portfolios.

• Technology platforms: Ultra-sensitive immunoassays, next-generation sequencing, digital polymerase chain reaction, and mass spectrometry differentiate providers.

• Innovation focus: Liquid biopsy and circulating tumor DNA, plasma tau neurological markers, multi-biomarker panels, and AI-driven interpretation.

 

Blood Based Biomarkers Market Recent Developmental Activities

In May 2025, Fujirebio Holdings, Inc., received FDA 510(k) clearance for its Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based in vitro diagnostic in the United States to aid identification of amyloid pathology associated with Alzheimer's disease. Strategic significance: Opened the era of FDA-cleared Alzheimer's blood testing and accelerated clinical adoption.

In August 2025, Laboratory Corporation of America Holdings, launched the FDA-cleared Alzheimer's plasma biomarker blood test nationwide, broadening patient access across the United States. Strategic significance: Demonstrated rapid laboratory-network scale-up of Alzheimer's blood testing and expanded clinical reach.

In October 2025, F. Hoffmann-La Roche Ltd, received FDA clearance for its Elecsys pTau181 test, a blood-based biomarker test indicated as an adjunct in early evaluation for Alzheimer's disease and cognitive impairment in the primary-care setting. Strategic significance: Extended FDA-cleared Alzheimer's blood testing into primary care and broadened access.

In April 2024, F. Hoffmann-La Roche Ltd (with Eli Lilly), received FDA Breakthrough Device Designation for its Elecsys pTau217 plasma biomarker test for identifying amyloid pathology in Alzheimer's disease. Strategic significance: Advanced a high-performing plasma tau test toward clearance and validated blood-based Alzheimer's diagnosis.

In April 2024, Abbott Laboratories, received FDA clearance for its i-STAT TBI cartridge, a handheld point-of-care test that detects traumatic brain injury biomarkers in blood within minutes without centrifugation. Strategic significance: Extended blood-based biomarkers into point-of-care brain-injury assessment in non-clinical and acute settings.

In July 2024, Biogen Inc., Beckman Coulter, Inc., and Fujirebio, announced a strategic collaboration to identify and develop minimally invasive, blood-based biomarkers specific to tau pathology in Alzheimer's disease for patient stratification and treatment monitoring. Strategic significance: Aligned therapeutics and diagnostics expertise to accelerate blood-based tau testing.

In December 2024, Fujirebio Holdings, Inc. (with Eisai Co. Ltd.), entered a memorandum of understanding for joint research and social implementation of novel blood-based biomarkers in neurodegenerative diseases, including plasma phosphorylated tau 217 diagnostics. Strategic significance: Strengthened the pipeline for blood-based neurodegenerative diagnostics and clinical implementation.

In October 2024, the World Health Organization, launched preferred product characteristics for blood-based biomarker diagnostics for Alzheimer's disease to guide development toward optimal clinical performance. Strategic significance: Provided a global framework that supports development, validation, and adoption of Alzheimer's blood tests.

In July 2025, the Alzheimer's Association, unveiled its first clinical practice guideline for the use of blood-based biomarker tests in the diagnostic evaluation of Alzheimer's disease, endorsing high-performing tests for triage and, in appropriate patients, substitution for imaging or spinal-fluid testing. Strategic significance: Provided authoritative clinical guidance that lowers adoption friction and supports payer uptake.

In November 2024, Harbinger Health, Inc., presented blood-based early cancer-detection data across multiple abstracts at an AACR special conference, showcasing biomarkers enabling cost-effective, early-stage cancer detection using liquid biopsy. Strategic significance: Advanced blood-based multi-cancer early detection and broadened the oncology biomarker pipeline.

In January 2024, Cleveland Diagnostics, Inc., raised over USD 75 million in growth capital led by Novo Holdings to accelerate development of non-invasive, blood-based diagnostic tests, including its IsoPSA prostate cancer test. Strategic significance: Strengthened funding for non-invasive blood-based oncology diagnostics.

In 2025, Quest Diagnostics Incorporated, reported performance data for its AD-Detect blood test showing over 90% sensitivity and specificity for Alzheimer's pathology in presented analyses. Strategic significance: Reinforced the clinical performance and laboratory availability of blood-based Alzheimer's testing at scale.

 

Blood Based Biomarkers Market Segmentation

Blood Based Biomarkers Market by Type

• Genetic Biomarkers

• Protein Biomarkers

• Cellular Biomarkers

• Metabolite Biomarkers

Blood Based Biomarkers Market by Application

• Oncology

• Cardiovascular Diseases

• Neurological Diseases

• Metabolic and Other Diseases

Blood Based Biomarkers Market by Technology

• Immunoassays

• Polymerase Chain Reaction

• Next-Generation Sequencing

• Mass Spectrometry

• Others

Blood Based Biomarkers Market by Sample Type

• Whole Blood

• Plasma

• Serum

Blood Based Biomarkers Market by End User

• Hospital and Diagnostic Laboratories

• Reference Laboratories

• Academic and Research Institutes

• Pharmaceutical and Biotechnology Companies

Blood Based Biomarkers Market by Geography

• North America Blood Based Biomarkers Market

• United States Blood Based Biomarkers Market Size in USD million (2023-2034)

• Canada Blood Based Biomarkers Market Size in USD million (2023-2034)

• Mexico Blood Based Biomarkers Market Size in USD million (2023-2034)

• Europe Blood Based Biomarkers Market

• Germany Blood Based Biomarkers Market Size in USD million (2023-2034)

• United Kingdom Blood Based Biomarkers Market Size in USD million (2023-2034)

• France Blood Based Biomarkers Market Size in USD million (2023-2034)

• Italy Blood Based Biomarkers Market Size in USD million (2023-2034)

• Spain Blood Based Biomarkers Market Size in USD million (2023-2034)

• Rest of Europe Blood Based Biomarkers Market Size in USD million (2023-2034)

• Asia-Pacific Blood Based Biomarkers Market

• China Blood Based Biomarkers Market Size in USD million (2023-2034)

• Japan Blood Based Biomarkers Market Size in USD million (2023-2034)

• India Blood Based Biomarkers Market Size in USD million (2023-2034)

• South Korea Blood Based Biomarkers Market Size in USD million (2023-2034)

• Australia Blood Based Biomarkers Market Size in USD million (2023-2034)

• Rest of Asia-Pacific Blood Based Biomarkers Market Size in USD million (2023-2034)

• Rest of the World (RoW) Blood Based Biomarkers Market

• Middle East Blood Based Biomarkers Market Size in USD million (2023-2034)

• Africa Blood Based Biomarkers Market Size in USD million (2023-2034)

• South America Blood Based Biomarkers Market Size in USD million (2023-2034)

 

Blood Based Biomarkers Market Recent Industry Trends and Milestones (2023-2026)

 

Blood Based Biomarkers Market Startup Funding and Investment Trends

Investment in the blood based biomarkers ecosystem has concentrated on liquid biopsy, ultra-sensitive neurological biomarkers, and AI-driven multi-biomarker platforms. The following companies illustrate recent funding and investment activity and technology focus.

Capital is flowing toward developers that combine high-sensitivity detection with strong clinical evidence in oncology and neurology. C2N Diagnostics and ALZpath advance plasma amyloid and tau testing for Alzheimer's, while Alamar Biosciences scales ultra-sensitive proteomics and Harbinger Health pursues methylation-based liquid biopsy for early cancer detection. Cleveland Diagnostics, backed by Novo Holdings, advances protein-structure-based prostate testing. Strategic capital is also entering through diagnostics and pharmaceutical alliances, such as Biogen with Beckman Coulter and Fujirebio and Fujirebio with Eisai. Collectively, these investments signal conviction that ultra-sensitive immunoassays, liquid biopsy, plasma tau testing, and AI-driven multi-biomarker panels will define the next phase of competitive advantage in the global Blood Based Biomarkers market.

 

Key Takeaways from the Blood Based Biomarkers Market Report Study

• Market size analysis for the current blood based biomarkers market size (2025), and market forecast for 9 years (2026 to 2034).

• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.

• Key companies dominating the global blood based biomarkers market.

• Various opportunities available for competitors in the blood based biomarkers market space.

• What are the top-performing segments in 2025? How will these segments perform in 2034?

• Which are the top-performing regions and countries in the current blood based biomarkers market scenario?

• Which are the regions and countries where companies should concentrate their opportunities for blood based biomarkers market growth in the future?

Target audience who can benefit from this blood based biomarkers market report study 

• Blood Based Biomarkers product providers

• Research organizations and consulting companies

• Blood Based Biomarkers-related organizations, associations, forums, and other alliances

• Government and corporate offices

• Start-up companies, venture capitalists, and private equity firms

• Distributors and traders dealing in blood based biomarkers

• Various end-users who want to know more about the blood based biomarkers market and the latest technological developments in the blood based biomarkers market.